Triple-negative breast cancer (TNBC) accounts for 15–20% of breast cancers that lack estrogen receptor (ER) and progesterone receptor (PR) expression and human epidermal growth factor 2 (HER2) amplification (Perou et al., 2000; Harbeck and Gnant, 2017). The gene discussed is ESR1; the disease is breast cancer.